ORCID Profile
0000-0001-9152-8799
Current Organisations
Macquarie University
,
Vall d'Hebron University Hospital
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: SPIE
Date: 09-07-2018
DOI: 10.1117/12.2313170
Publisher: Springer Science and Business Media LLC
Date: 10-11-2015
DOI: 10.1038/NCOMMS9839
Abstract: Cell-free circulating tumour DNA (ctDNA) in plasma has been shown to be informative of the genomic alterations present in tumours and has been used to monitor tumour progression and response to treatments. However, patients with brain tumours do not present with or present with low amounts of ctDNA in plasma precluding the genomic characterization of brain cancer through plasma ctDNA. Here we show that ctDNA derived from central nervous system tumours is more abundantly present in the cerebrospinal fluid (CSF) than in plasma. Massively parallel sequencing of CSF ctDNA more comprehensively characterizes the genomic alterations of brain tumours than plasma, allowing the identification of actionable brain tumour somatic mutations. We show that CSF ctDNA levels longitudinally fluctuate in time and follow the changes in brain tumour burden providing biomarkers to monitor brain malignancies. Moreover, CSF ctDNA is shown to facilitate and complement the diagnosis of leptomeningeal carcinomatosis.
Publisher: Springer Science and Business Media LLC
Date: 29-06-2017
DOI: 10.1038/S41523-017-0026-6
Abstract: Several studies have demonstrated the feasibility of molecular screening of tumour s les for matching patients with cancer to targeted therapies. However, most of them have been carried out at institutional or national level. Herein, we report on the pilot phase of AURORA (NCT02102165), a European multinational collaborative molecular screening initiative for advanced breast cancer patients. Forty-one patients were prospectively enroled at four participating centres across Europe. Metastatic tumours were biopsied and profiled using an Ion Torrent sequencing platform at a central facility. Sequencing results were obtained for 63% of the patients in real-time with variable turnaround time stemming from delays between patient consent and biopsy. At least one clinically actionable mutation was identified in 73% of patients. We used the Illumina sequencing technology for orthogonal validation and achieved an average of 66% concordance of substitution calls per patient. Additionally, copy number aberrations inferred from the Ion Torrent sequencing were compared to single nucleotide polymorphism arrays and found to be 59% concordant on average. Although this study demonstrates that powerful next generation genomic techniques are logistically ready for international molecular screening programs in routine clinical settings, technical challenges remain to be addressed in order to ensure the accuracy and clinical utility of the genomic data.
Publisher: Elsevier BV
Date: 11-2018
Publisher: Impact Journals, LLC
Date: 17-04-2018
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/2159-8290.22540795
Abstract: File with the supplementary material & methods, supplementary tables and supplementary figure.
Publisher: The Optical Society
Date: 06-10-2017
DOI: 10.1364/OE.25.025546
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/2159-8290.22540798
Abstract: Supplementary file with the listing of the liver genes excluded from transcriptomic analyses.
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/2159-8290.22540795.V1
Abstract: File with the supplementary material & methods, supplementary tables and supplementary figure.
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/2159-8290.C.6549478.V1
Abstract: Abstract AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 targeted gene sequencing, 152 RNA sequencing, 67 single nucleotide polymorphism arrays), we found a driver role for i GATA1 /i and i MEN1 /i somatic mutations. Metastases were enriched in i ESR1, PTEN, CDH1, PIK3CA /i , and i RB1 /i mutations i MDM4 /i and i MYC /i lifications and i ARID1A /i deletions. An increase in clonality was observed in driver genes such as i ERBB2 /i and i RB1 /i . Intrinsic subtype switching occurred in 36% of cases. Luminal A/B to HER2-enriched switching was associated with i TP53 /i and/or i PIK3CA /i mutations. Metastases had lower immune score and increased immune-permissive cells. High tumor mutational burden correlated to shorter time to relapse in HR sup + /sup /HER2 sup − /sup cancers. ESCAT tier I/II alterations were detected in 51% of patients and matched therapy was used in 7%. Integration of multi-omics analyses in clinical practice could affect treatment strategies in MBC. Significance: The AURORA program, through the genomic and transcriptomic analyses of matched primary and metastatic s les from 381 patients with breast cancer, coupled with prospectively collected clinical data, identified genomic alterations enriched in metastases and prognostic biomarkers. ESCAT tier I/II alterations were detected in more than half of the patients. i a href="ancerdiscovery/article/doi/10.1158/2159-8290.CD-11-11-ITI" target="_blank" This article is highlighted in the In This Issue feature, p. 2659 /a /i /
Publisher: American Astronomical Society
Date: 03-08-2023
Abstract: TOI-1899 b is a rare exoplanet, a temperate warm Jupiter orbiting an M dwarf, first discovered by Cañas et al. (2020) from a TESS single-transit event. Using new radial velocities (RVs) from the precision RV spectrographs HPF and NEID, along with additional TESS photometry and ground-based transit follow-up, we are able to derive a much more precise orbital period of P = 29.090312 − 0.000035 + 0.000036 days, along with a radius of R p = 0.99 ± 0.03 R J . We have also improved the constraints on planet mass, M p = 0.67 ± 0.04 M J , and eccentricity, which is consistent with a circular orbit at 2 σ ( e = 0.044 − 0.027 + 0.029 ). TOI-1899 b occupies a unique region of parameter space as the coolest known ( T eq ≈ 380 K) Jovian-sized transiting planet around an M dwarf we show that it has great potential to provide clues regarding the formation and migration mechanisms of these rare gas giants through transmission spectroscopy with JWST, as well as studies of tidal evolution.
Publisher: SPIE
Date: 09-08-2016
DOI: 10.1117/12.2233743
Publisher: Springer Science and Business Media LLC
Date: 31-08-2016
Publisher: SPIE
Date: 06-07-2018
DOI: 10.1117/12.2312939
Publisher: SPIE
Date: 13-12-2020
DOI: 10.1117/12.2561930
Publisher: American Association for Cancer Research (AACR)
Date: 28-06-2021
DOI: 10.1158/2159-8290.CD-20-1647
Abstract: The AURORA program, through the genomic and transcriptomic analyses of matched primary and metastatic s les from 381 patients with breast cancer, coupled with prospectively collected clinical data, identified genomic alterations enriched in metastases and prognostic biomarkers. ESCAT tier I/II alterations were detected in more than half of the patients. This article is highlighted in the In This Issue feature, p. 2659
Publisher: SPIE
Date: 26-07-2016
DOI: 10.1117/12.2234294
Publisher: SPIE
Date: 13-12-2020
DOI: 10.1117/12.2561433
Publisher: SPIE
Date: 09-08-2016
DOI: 10.1117/12.2232371
Publisher: SPIE
Date: 06-07-2010
DOI: 10.1117/12.2314336
Publisher: SPIE
Date: 06-07-2018
DOI: 10.1117/12.2312399
Publisher: SPIE
Date: 30-08-2022
DOI: 10.1117/12.2630017
Publisher: SPIE
Date: 13-12-2020
DOI: 10.1117/12.2560626
Publisher: American Association for Cancer Research (AACR)
Date: 03-04-2023
DOI: 10.1158/2159-8290.22540798.V1
Abstract: Supplementary file with the listing of the liver genes excluded from transcriptomic analyses.
Publisher: American Astronomical Society
Date: 07-2023
Abstract: Warm Jupiters are close-in giant planets with relatively large planet–star separations (i.e., 10 a / R ⋆ 100). Given their weak tidal interactions with their host stars, measurements of stellar obliquity may be used to probe the initial obliquity distribution and dynamical history for close-in gas giants. Using spectroscopic observations, we confirm the planetary nature of TOI-1859b and determine the stellar obliquity of TOI-1859 to be λ = 38.9 − 2.7 + 2.8 ° relative to its planetary companion using the Rossiter–McLaughlin effect. TOI-1859b is a 64 day warm Jupiter orbiting around a late F dwarf and has an orbital eccentricity of 0.57 − 0.16 + 0.12 inferred purely from transit light curves. The eccentric and misaligned orbit of TOI-1859b is likely an outcome of dynamical interactions, such as planet–planet scattering and planet–disk resonance crossing.
Publisher: American Astronomical Society
Date: 14-07-2022
Abstract: We confirm the planetary nature of two gas giants discovered by the Transiting Exoplanet Survey Satellite to transit M dwarfs. TOI-3714 ( V = 15.24, J = 11.74) is an M2 dwarf hosting a hot Jupiter ( M p = 0.70 ± 0.03 M J and R p = 1.01 ± 0.03 R J ) on an orbital period of 2.154849 ± 0.000001 days with a resolved white dwarf companion. TOI-3629 ( V = 14.63, J = 11.42) is an M1 dwarf hosting a hot Jupiter ( M p = 0.26 ± 0.02 M J and R p =0.74 ± 0.02 R J ) on an orbital period of 3.936551 − 0.000006 + 0.000005 days. We characterize each transiting companion using a combination of ground-based and space-based photometry, speckle imaging, and high-precision velocimetry from the Habitable-zone Planet Finder and the NEID spectrographs. With the discovery of these two systems, there are now nine M dwarfs known to host transiting hot Jupiters. Among this population, TOI-3714 b ( T eq = 750 ± 20 K and TSM = 98 ± 7) and TOI-3629 b ( T eq = 690 ± 20 K and TSM = 80 ± 9) are warm gas giants amenable to additional characterization with transmission spectroscopy to probe atmospheric chemistry and, for TOI-3714, obliquity measurements to probe formation scenarios.
Publisher: Elsevier BV
Date: 09-2014
Location: Australia
Location: Spain
Location: Portugal
No related grants have been discovered for Mafalda Oliveira.